Focuses on the U.S. Food and Drug Administration's (FDA) action plan for regulating xenotransplant products and procedures. Clinical trials of several experimental xenotransplant products and procedures; Concerns of the FDA regarding Massachusetts-based Genzyme Tissue Repair's quasi-xenotransplant procedure for growing skin grafts; Criticism of FDA recommendations by blood suppliers.